Blood Plasma Derivatives Market Analysis, Trends, and Scope 2023 to 2028
Blood Plasma Derivatives Market Report Scope
| Report Attribute | Details |
|---|---|
| Market size in 2022 | US$ 29.89 Billion |
| Market Size by 2028 | US$ 51.12 Billion |
| Global CAGR (2022 - 2028) | 9.4% |
| Historical Data | 2020-2021 |
| Forecast period | 2023-2028 |
| Segments Covered |
By Type
|
| Regions and Countries Covered | North America
|
| Market leaders and key company profiles |
Blood Plasma Derivatives – Market Segmentation
Based on type, the blood plasma derivatives market is segmented into albumin, factor VIII, factor IX, immunoglobulin, hyperimmune globulin, and others. The market for the immunoglobulin segment is further segmented into IgG, IgM, IgA, IgD, and IgE. By application, the blood plasma derivatives market is segmented into hemophilia, hypogammaglobulinemia, immunodeficiency diseases, von Willebrand disease, and other applications. The market, by end user, is segmented into hospitals, clinics, and others. Based on geography, the blood plasma derivatives market is segmented into North America (the US, Canada, and Mexico), Europe (France, Germany, the UK, Italy, Spain, and the Rest of Europe), Asia Pacific (China, Japan, India, Australia, South Korea, and the Rest of Asia Pacific), the Middle East & Africa (Saudi Arabia, South Africa, the UAE, and the Rest of Middle East & Africa), and South & Central America (Brazil, Argentina, and the Rest of South & Central America).
Company Profiles – Blood Plasma Derivatives Market
- Grifols, S.A.
- SK Plasma Co., Ltd.
- Fusion Healthcare
- Biotest AG
- Green Cross Corp
- Kedrion
- LFB S.A.
- Octapharma AG
- CSL Limited
- Takeda Pharmaceutical Company Limited
Get Free Sample For